Multiplexing Prism for Monocular Vision
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new device called a multiplexing prism, designed to expand the field of view for individuals who have lost vision in one eye. The trial aims to determine if a simpler design of this device can make a significant impact. Individuals who have experienced vision loss in one eye for over a year and have good vision in the remaining eye may qualify for this trial. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could significantly enhance the quality of life for those with vision loss.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this device is safe for individuals with acquired monocular vision?
Research shows that the multiplexing prism is designed to help individuals who have lost one eye by widening their field of vision. Although specific safety data for this device is unavailable, it functions like a pair of glasses, making it non-invasive. Previous studies have not reported health issues, such as seizures or movement problems, among users, suggesting it is generally well-tolerated.
This trial, not in a traditional phase, focuses on improving the device's design rather than testing drug safety, which is usually more complex. The absence of reported side effects in earlier studies supports the idea that this device is likely safe, though ongoing research will help confirm this.12345Why are researchers excited about this trial?
The Multiplexing Prism is unique because it offers a novel way to expand the field of view for individuals with monocular vision, specifically by addressing the blind side of vision. Unlike traditional treatments that might focus on rehabilitation exercises or compensatory strategies, this prism uses an optical approach to directly enhance the visual field on the nasal side. Researchers are excited about this treatment because it has the potential to provide immediate and tangible improvements in vision, making everyday tasks easier and safer for those affected by monocular vision.
What evidence suggests that the multiplexing prism is effective for expanding the field of view in individuals with monocular vision?
Research has shown that the multiplexing prism (MxP), used by participants in this trial, can significantly improve the field of view for individuals who have lost vision in one eye. Studies have found that the MxP expands the field of view by about 25 degrees, enabling users to see more of their surroundings, particularly on the side of the blind eye. Participants using the MxP performed better in tasks requiring environmental awareness, such as spotting potential hazards while walking. The device addresses a common issue called apical scotoma, a blind spot. Overall, these findings suggest that the MxP effectively enhances vision for those with vision in only one eye.12356
Who Is on the Research Team?
Eli Peli, OD
Principal Investigator
Schepens Eye Research Institute
Are You a Good Fit for This Trial?
This trial is for people who have lost vision in one eye for more than a year, but still have good vision (better than 20/32) in their other eye without any field defects. They should not have health issues like seizures or motor movement problems.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are fitted with the multiplexing prism to expand the field of view
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Multiplexing Prism
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts Eye and Ear Infirmary
Lead Sponsor
National Eye Institute (NEI)
Collaborator